Navin Pinto
Overview
Explore the profile of Navin Pinto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
994
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gust J, Cole B, Ronsley R, Wilson A, Seidel K, Wendler J, et al.
Neuro Oncol
. 2025 Mar;
PMID: 40070357
Background: Relapsed/refractory pediatric CNS tumors have a poor prognosis. EGFR is commonly overexpressed, but EGFRvIII mutations are uncommon. To target these tumors, we used chimeric antigen receptor (CAR) T cells...
2.
Sokol E, LaBarre B, Pinto N, Kreissman S, Granger M, Park J, et al.
EJC Paediatr Oncol
. 2025 Jan;
4.
PMID: 39822770
Background: Response to induction chemotherapy has been shown to predict outcome in patients with high-risk neuroblastoma (HR-NB), with those achieving a complete response (CR) having superior outcomes. Methods: We evaluated...
3.
Vitanza N, Ronsley R, Choe M, Seidel K, Huang W, Rawlings-Rhea S, et al.
Nat Med
. 2025 Jan;
PMID: 39775044
Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor that confers a median survival of 11 months. As B7-H3 is expressed on pediatric CNS tumors, we...
4.
Pinto N, Albert C, Taylor M, Ullom H, Wilson A, Huang W, et al.
J Clin Oncol
. 2024 Sep;
42(35):4163-4172.
PMID: 39255444
Purpose: B7-H3 is an immunoregulatory protein overexpressed by many pediatric solid tumors with limited expression on critical organs, making it an attractive immunotherapy target. We present a first-in-human phase I...
5.
Vitanza N, Choe M, Brown C, Beebe A, Kong A, Rogers L, et al.
J Hematol Oncol Pharm
. 2024 Sep;
14(4):148-154.
PMID: 39238483
Background: A major obstacle in translating the therapeutic potential of chimeric antigen receptor (CAR) T cells to children with central nervous system (CNS) tumors is the blood-brain barrier. To overcome...
6.
Bagatell R, Park J, Acharya S, Aldrink J, Allison J, Alva E, et al.
J Natl Compr Canc Netw
. 2024 Aug;
22(6):413-433.
PMID: 39151455
Neuroblastoma is the most common extracranial solid tumor diagnosed in children. This inaugural version of the NCCN Guidelines for Neuroblastoma provides recommendations for the diagnosis, risk classification, and treatment of...
7.
Navarro S, Pinto N, Hawkins D, Park J, Dilmaghani S, Rimorin C, et al.
Cancer Chemother Pharmacol
. 2024 Jul;
94(4):627-633.
PMID: 39080017
Purpose: 4-hydroxycyclophosphamide (4HCY) is the principal precursor to the cytotoxic metabolite of cyclophosphamide (CY), which is often used as first-line treatment of children with cancer. There is conflicting data regarding...
8.
Goldsmith K, Park J, Kayser K, Malvar J, Chi Y, Groshen S, et al.
Nat Med
. 2023 Apr;
29(5):1092-1102.
PMID: 37012551
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy in children...
9.
Marinoff A, Spurr L, Fong C, Li Y, Forrest S, Ward A, et al.
JCO Precis Oncol
. 2023 Mar;
7:e2200334.
PMID: 36996377
Purpose: Osteosarcoma risk stratification, on the basis of the presence of metastatic disease at diagnosis and histologic response to chemotherapy, has remained unchanged for four decades, does not include genomic...
10.
Pinto N, Naranjo A, Ding X, Zhang F, Hibbitts E, Kennedy R, et al.
Clin Cancer Res
. 2023 Feb;
29(8):1546-1556.
PMID: 36749880
Purpose: Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neuroblastoma populations....